Status:
COMPLETED
CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response
Lead Sponsor:
University College, London
Conditions:
Viraemia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to see how well the antibody levels found months to years after patients entered a previous randomised placebo-controlled trial of a glycoprotein B vaccine against cytomeg...
Detailed Description
This is a follow up study to a randomised controlled trial comparing a CMV glycoprotein B vaccine with placebo (Trial title: A Phase II Immunogenicity Trial Of Cytomegalovirus Glycoprotein B Vaccine I...
Eligibility Criteria
Inclusion
- Recipient of IMP (Investigational Medicinal product) (CMV gB vaccine or placebo) in trial 'Phase II Immunogenicity Trial Of Cytomegalovirus Glycoprotein B Vaccine In Allograft Candidate Recipients Study' (CTA ref no 20363/0238/001-0010; REC ref no 5476; UCL sponsor no 05/009).
- Informed consent must be obtained from the patient.
Exclusion
- 1\. Patient unable or unwilling to provide and sign an informed consent.
Key Trial Info
Start Date :
September 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01883206
Start Date
September 1 2013
End Date
February 1 2016
Last Update
October 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Free Hospital
London, United Kingdom, NW3 2QG